Literature DB >> 10665989

Increased brain P-glycoprotein in morphine tolerant rats.

C L Aquilante1, S P Letrent, G M Pollack, K L Brouwer.   

Abstract

The objective of this study was to determine whether chronic morphine exposure increased P-glycoprotein in rat brain. Male Sprague-Dawley rats were treated with morphine, saline, or dexamethasone for 5 days. On day 6, antinociceptive effect was measured to evaluate the extent of functional tolerance to morphine. Brain P-glycoprotein was detected by Western blot analysis of whole brain homogenate. Morphine- and dexamethasone-treated rats exhibited decreased antinociceptive response when compared to saline-treated controls. Brain P-glycoprotein was approximately 2-fold higher in morphine-treated rats compared to saline controls based on Western blot analysis. Chronic morphine exposure appears to increase P-glycoprotein in rat brain. P-glycoprotein induction may enhance morphine efflux from the brain, thus reducing morphine's pharmacologic activity. Induction of P-glycoprotein may be one mechanism involved in the development of morphine tolerance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10665989     DOI: 10.1016/s0024-3205(99)00599-8

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  35 in total

1.  Opioids and efflux transporters. Part 1: P-glycoprotein substrate activity of N-substituted analogs of meperidine.

Authors:  Susan L Mercer; Hazem E Hassan; Christopher W Cunningham; Natalie D Eddington; Andrew Coop
Journal:  Bioorg Med Chem Lett       Date:  2006-12-21       Impact factor: 2.823

2.  When it comes to opiates, just say NO.

Authors:  Gavril W Pasternak
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

3.  Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation.

Authors:  Hazem E Hassan; Alan L Myers; Andrew Coop; Natalie D Eddington
Journal:  J Pharm Sci       Date:  2009-12       Impact factor: 3.534

4.  Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective.

Authors:  Emily O Dumas; Gary M Pollack
Journal:  AAPS J       Date:  2008-11-07       Impact factor: 4.009

Review 5.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

Review 6.  Prescription Opioid Fatalities: Examining Why the Healer Could be the Culprit.

Authors:  Adeleke D Adewumi; Christine E Staatz; Samantha A Hollingworth; Jason P Connor; Rosa Alati
Journal:  Drug Saf       Date:  2018-11       Impact factor: 5.606

7.  HIV-1 Tat and opioids act independently to limit antiretroviral brain concentrations and reduce blood-brain barrier integrity.

Authors:  Crystal R Leibrand; Jason J Paris; Austin M Jones; Quamrun N Masuda; Matthew S Halquist; Woong-Ki Kim; Pamela E Knapp; Angela D M Kashuba; Kurt F Hauser; MaryPeace McRae
Journal:  J Neurovirol       Date:  2019-05-17       Impact factor: 2.643

8.  Regulation of gene expression in brain tissues of rats repeatedly treated by the highly abused opioid agonist, oxycodone: microarray profiling and gene mapping analysis.

Authors:  Hazem E Hassan; Alan L Myers; Insong J Lee; Hegang Chen; Andrew Coop; Natalie D Eddington
Journal:  Drug Metab Dispos       Date:  2010-01       Impact factor: 3.922

Review 9.  Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.

Authors:  Robert Gharavi; William Hedrich; Hongbing Wang; Hazem E Hassan
Journal:  Pharm Res       Date:  2015-05-14       Impact factor: 4.200

10.  Stabilization of morphine tolerance with long-term dosing: association with selective upregulation of mu-opioid receptor splice variant mRNAs.

Authors:  Jin Xu; Andrew J Faskowitz; Grace C Rossi; Mingming Xu; Zhigang Lu; Ying-Xian Pan; Gavril W Pasternak
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.